Literature DB >> 25749299

TAAR1 Modulates Cortical Glutamate NMDA Receptor Function.

Stefano Espinoza1, Gabriele Lignani1, Lucia Caffino2, Silvia Maggi1, Ilya Sukhanov3, Damiana Leo1, Liudmila Mus1, Marco Emanuele1, Giuseppe Ronzitti1, Anja Harmeier4, Lucian Medrihan1, Tatyana D Sotnikova5, Evelina Chieregatti1, Marius C Hoener4, Fabio Benfenati1, Valter Tucci1, Fabio Fumagalli2, Raul R Gainetdinov6.   

Abstract

Trace Amine-Associated Receptor 1 (TAAR1) is a G protein-coupled receptor expressed in the mammalian brain and known to influence subcortical monoaminergic transmission. Monoamines, such as dopamine, also play an important role within the prefrontal cortex (PFC) circuitry, which is critically involved in high-o5rder cognitive processes. TAAR1-selective ligands have shown potential antipsychotic, antidepressant, and pro-cognitive effects in experimental animal models; however, it remains unclear whether TAAR1 can affect PFC-related processes and functions. In this study, we document a distinct pattern of expression of TAAR1 in the PFC, as well as altered subunit composition and deficient functionality of the glutamate N-methyl-D-aspartate (NMDA) receptors in the pyramidal neurons of layer V of PFC in mice lacking TAAR1. The dysregulated cortical glutamate transmission in TAAR1-KO mice was associated with aberrant behaviors in several tests, indicating a perseverative and impulsive phenotype of mutants. Conversely, pharmacological activation of TAAR1 with selective agonists reduced premature impulsive responses observed in the fixed-interval conditioning schedule in normal mice. Our study indicates that TAAR1 plays an important role in the modulation of NMDA receptor-mediated glutamate transmission in the PFC and related functions. Furthermore, these data suggest that the development of TAAR1-based drugs could provide a novel therapeutic approach for the treatment of disorders related to aberrant cortical functions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25749299      PMCID: PMC4613611          DOI: 10.1038/npp.2015.65

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  39 in total

1.  Regulation of spine morphology and spine density by NMDA receptor signaling in vivo.

Authors:  Sila K Ultanir; Ji-Eun Kim; Benjamin J Hall; Thomas Deerinck; Mark Ellisman; Anirvan Ghosh
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-28       Impact factor: 11.205

2.  Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: role of D2 dopamine autoreceptors.

Authors:  D Leo; L Mus; S Espinoza; M C Hoener; T D Sotnikova; R R Gainetdinov
Journal:  Neuropharmacology       Date:  2014-02-22       Impact factor: 5.250

3.  Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress.

Authors:  Fabio Fumagalli; Francesca Calabrese; Alessia Luoni; Francesca Bolis; Giorgio Racagni; Marco A Riva
Journal:  Int J Neuropsychopharmacol       Date:  2011-02-24       Impact factor: 5.176

Review 4.  New targets for pharmacological intervention in the glutamatergic synapse.

Authors:  Fabrizio Gardoni; Monica Di Luca
Journal:  Eur J Pharmacol       Date:  2006-06-15       Impact factor: 4.432

5.  Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor.

Authors:  J R Bunzow; M S Sonders; S Arttamangkul; L M Harrison; G Zhang; D I Quigley; T Darland; K L Suchland; S Pasumamula; J L Kennedy; S B Olson; R E Magenis; S G Amara; D K Grandy
Journal:  Mol Pharmacol       Date:  2001-12       Impact factor: 4.436

6.  Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics.

Authors:  Florent G Revel; Jean-Luc Moreau; Raul R Gainetdinov; Antonio Ferragud; Clara Velázquez-Sánchez; Tatyana D Sotnikova; Stephen R Morairty; Anja Harmeier; Katrin Groebke Zbinden; Roger D Norcross; Amyaouch Bradaia; Thomas S Kilduff; Barbara Biemans; Bruno Pouzet; Marc G Caron; Juan J Canales; Tanya L Wallace; Joseph G Wettstein; Marius C Hoener
Journal:  Biol Psychiatry       Date:  2012-06-16       Impact factor: 13.382

Review 7.  Trace amine-associated receptors as emerging therapeutic targets.

Authors:  Tatyana D Sotnikova; Marc G Caron; Raul R Gainetdinov
Journal:  Mol Pharmacol       Date:  2009-04-23       Impact factor: 4.436

Review 8.  Neural circuits subserving behavioral flexibility and their relevance to schizophrenia.

Authors:  Stan B Floresco; Ying Zhang; Takeshi Enomoto
Journal:  Behav Brain Res       Date:  2008-12-06       Impact factor: 3.332

Review 9.  Inhibition and impulsivity: behavioral and neural basis of response control.

Authors:  Andrea Bari; Trevor W Robbins
Journal:  Prog Neurobiol       Date:  2013-07-13       Impact factor: 11.685

Review 10.  Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy.

Authors:  Mark J Millan; Yves Agid; Martin Brüne; Edward T Bullmore; Cameron S Carter; Nicola S Clayton; Richard Connor; Sabrina Davis; Bill Deakin; Robert J DeRubeis; Bruno Dubois; Mark A Geyer; Guy M Goodwin; Philip Gorwood; Thérèse M Jay; Marian Joëls; Isabelle M Mansuy; Andreas Meyer-Lindenberg; Declan Murphy; Edmund Rolls; Bernd Saletu; Michael Spedding; John Sweeney; Miles Whittington; Larry J Young
Journal:  Nat Rev Drug Discov       Date:  2012-02-01       Impact factor: 84.694

View more
  39 in total

Review 1.  Pathological Overeating: Emerging Evidence for a Compulsivity Construct.

Authors:  Catherine F Moore; Valentina Sabino; George F Koob; Pietro Cottone
Journal:  Neuropsychopharmacology       Date:  2016-12-06       Impact factor: 7.853

2.  Trace amine-associated receptor 1 regulation of methamphetamine-induced neurotoxicity.

Authors:  Nicholas B Miner; Josh S Elmore; Michael H Baumann; Tamara J Phillips; Aaron Janowsky
Journal:  Neurotoxicology       Date:  2017-09-15       Impact factor: 4.294

Review 3.  TAAR1 and Psychostimulant Addiction.

Authors:  Jianfeng Liu; Ruyan Wu; Jun-Xu Li
Journal:  Cell Mol Neurobiol       Date:  2020-01-23       Impact factor: 5.046

4.  Possible role of rare variants in Trace amine associated receptor 1 in schizophrenia.

Authors:  Jibin John; Prachi Kukshal; Triptish Bhatia; K V Chowdari; V L Nimgaonkar; S N Deshpande; B K Thelma
Journal:  Schizophr Res       Date:  2017-02-24       Impact factor: 4.939

Review 5.  Dopamine D2 Receptor Supersensitivity as a Spectrum of Neurotoxicity and Status in Psychiatric Disorders.

Authors:  Richard M Kostrzewa; Karolina Wydra; Malgorzata Filip; Cynthia A Crawford; Sanders A McDougall; Russell W Brown; Dasiel O Borroto-Escuela; Kjell Fuxe; Raul R Gainetdinov
Journal:  J Pharmacol Exp Ther       Date:  2018-06-19       Impact factor: 4.030

6.  Minimal Age-Related Alterations in Behavioral and Hematological Parameters in Trace Amine-Associated Receptor 1 (TAAR1) Knockout Mice.

Authors:  I S Zhukov; L G Kubarskaya; I Y Tissen; A A Kozlova; S G Dagayev; V A Kashuro; O L Vlasova; E L Sinitca; I V Karpova; R R Gainetdinov
Journal:  Cell Mol Neurobiol       Date:  2019-08-09       Impact factor: 5.046

Review 7.  Neuropharmacology of compulsive eating.

Authors:  Catherine F Moore; Julia I Panciera; Valentina Sabino; Pietro Cottone
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-03-19       Impact factor: 6.237

8.  Role of TAAR1 within the Subregions of the Mesocorticolimbic Dopaminergic System in Cocaine-Seeking Behavior.

Authors:  Jian-Feng Liu; Justin N Siemian; Robert Seaman; Yanan Zhang; Jun-Xu Li
Journal:  J Neurosci       Date:  2017-01-25       Impact factor: 6.167

9.  Trace amine-associated receptor 1 agonism promotes wakefulness without impairment of cognition in Cynomolgus macaques.

Authors:  Anushka V Goonawardena; Stephen R Morairty; Ryan Dell; Gabriel A Orellana; Marius C Hoener; Tanya L Wallace; Thomas S Kilduff
Journal:  Neuropsychopharmacology       Date:  2019-04-06       Impact factor: 7.853

10.  Trace Amine-Associated Receptor 1 Regulates Wakefulness and EEG Spectral Composition.

Authors:  Michael D Schwartz; Sarah W Black; Simon P Fisher; Jeremiah B Palmerston; Stephen R Morairty; Marius C Hoener; Thomas S Kilduff
Journal:  Neuropsychopharmacology       Date:  2016-09-23       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.